BOSTON ( TheStreet) -- Welcome to November's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

Will FDA approve Transcept Pharmaceuticals' ( TSPT) middle-of-the-night sleeping pill Intermezzo next week? Will FDA accept Onyx Pharma's ( ONXX) multiple myeloma drug carfilzomib for accelerated review? Incyte's ( INCY) new myelofibrosis drug Jakafi was approved Wednesday, earlier than expected, but the stock reaction was muted. Let's discuss.

Can Vertex Pharmaceuticals ( VRTX) recover from its recent slump? Let's try to make sense of the changing hepatitis C therapy landscape with Idenix Pharmaceuticals ( IDIX), Pharmasset ( VRUS) and Inhibitex ( INHX).

Geron ( GERN) gives up on embryonic stem cells. Should Advanced Cell Technologies ( ACTC) do the same?

Will Amarin ( AMRN) ever resolve its AMR101 patent issues?

What does the future of prostate cancer treatment look like? Can Dendreon ( DNDN), Medivation ( MDVN), Exelixis ( EXEL) and Algeta all win, or will some of these companies lose?

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.